Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 1/2 1

Status

Completed 39Unknown 8Terminated 4Withdrawn 1Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Dermatologic 4CNS 3Gynecologic 2Tumor-Agnostic 1Breast 1

Conditions

Keratosis, Actinic 3Melanoma 1

Interventions

pembrolizumab 58Ipilimumab 53Cyclophosphamide 53Nivolumab 45aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 19dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11spartalizumab 10Filgrastim 10Dacarbazine 10cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Imiquimod × Dermatologic × Clear all
NCT04809662 2024-11-07

Comparing Immune Responses to Topical Imiquimod

University of California, Davis

Terminated
6 enrolled
Dermatologic

Keratosis, Actinic

NCT01191034 2019-03-12

Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 1/2 Terminated
2 enrolled
Dermatologic

Melanoma

NCT01538901 2017-09-12

AKtransplant

Medical University of Vienna

Phase 4 Terminated
10 enrolled
Dermatologic

Keratosis, Actinic

NCT01203878 2014-12-08

Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

Tennessee Clinical Research Center

Phase 4 Terminated
21 enrolled 10 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡